Advisors Asset Management, Inc. Mirati Therapeutics, Inc. Transaction History

Advisors Asset Management, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 08, 2022	SELL	$39.16 - $88.71 $39,238 - $88,887	-1,002 Reduced 63.38%	579 $39,000
Q1 2022 May 17, 2022	SELL	$75.82 - $150.97 $109,559 - $218,151	-1,445 Reduced 47.75%	1,581 $130,000
Q4 2021 Feb 15, 2022	SELL	$132.01 - $190.29 $16,105 - $23,215	-122 Reduced 3.88%	3,026 $444,000
Q3 2021 Nov 12, 2021	SELL	$132.13 - $177.45 $1,453 - $1,951	-11 Reduced 0.35%	3,148 $557,000
Q2 2021 Jul 30, 2021	BUY	$144.0 - $179.73 $175,680 - $219,270	1,220 Added 62.92%	3,159 $510,000
Q1 2021 May 07, 2021	BUY	$158.92 - $221.61 $201,669 - $281,223	1,269 Added 189.4%	1,939 $332,000
Q4 2020 Feb 12, 2021	BUY	$162.05 - $240.27 $108,573 - $160,980	670 New	670 $147,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Advisors Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Advisors Asset Management, Inc. with notifications on news.